WuXi Biologics (Cayman) Management

Management criteria checks 2/4

WuXi Biologics (Cayman)'s CEO is Chris Chen, appointed in Jan 2016, has a tenure of 8.25 years. total yearly compensation is CN¥78.67M, comprised of 3.8% salary and 96.2% bonuses, including company stock and options. directly owns 0.32% of the company’s shares, worth HK$184.17M. The average tenure of the management team and the board of directors is 2.4 years and 6.6 years respectively.

Key information

Chris Chen

Chief executive officer

CN¥78.7m

Total compensation

CEO salary percentage	3.8%
CEO tenure	8.3yrs
CEO ownership	0.3%
Management average tenure	2.4yrs
Board average tenure	6.6yrs

Recent management updates

Recent updates

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Apr 15

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Mar 04

Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

Dec 08

These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

Aug 26

WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

Aug 10

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

Jun 19

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

May 12

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Mar 25

At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

Mar 13

Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

Feb 13

An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Jan 30

Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Dec 09

Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching

Nov 20

With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case

Nov 08

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?

Oct 27

WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

Sep 08

Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?

Aug 15

We Ran A Stock Scan For Earnings Growth And WuXi Biologics (Cayman) (HKG:2269) Passed With Ease

Aug 02

Estimating The Intrinsic Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Jun 29

What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

May 16

Here's Why I Think WuXi Biologics (Cayman) (HKG:2269) Might Deserve Your Attention Today

May 03

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Apr 21

An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 42% Undervalued

Mar 26

Why We're Not Concerned Yet About WuXi Biologics (Cayman) Inc.'s (HKG:2269) 30% Share Price Plunge

Feb 09

CEO Compensation Analysis

How has Chris Chen's remuneration changed compared to WuXi Biologics (Cayman)'s earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	CN¥3b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥79m	CN¥3m	CN¥4b
Sep 30 2022	n/a	n/a	CN¥4b
Jun 30 2022	n/a	n/a	CN¥4b
Mar 31 2022	n/a	n/a	CN¥4b
Dec 31 2021	CN¥51m	CN¥3m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥2b
Dec 31 2020	CN¥31m	CN¥3m	CN¥2b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥25m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥922m
Jun 30 2019	n/a	n/a	CN¥831m
Mar 31 2019	n/a	n/a	CN¥731m
Dec 31 2018	CN¥20m	CN¥2m	CN¥631m
Sep 30 2018	n/a	n/a	CN¥520m
Jun 30 2018	n/a	n/a	CN¥410m
Mar 31 2018	n/a	n/a	CN¥331m
Dec 31 2017	CN¥24m	CN¥2m	CN¥253m

Compensation vs Market: Chris's total compensation ($USD10.86M) is above average for companies of similar size in the Hong Kong market ($USD924.12K).

Compensation vs Earnings: Chris's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Chris Chen (50 yo)

8.3yrs

Tenure

CN¥78,670,000

Compensation

Dr. Zhisheng Chen, also known as Chris, has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr. Chen i...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ge Li	Founder & Chairman	10.2yrs	no data	no data
Zhisheng Chen	CEO & Executive Director	8.3yrs	CN¥78.67m	0.32% CN¥ 184.2m
Weichang Zhou	Honorary President of Global Biologics Development	9yrs	CN¥24.98m	0.0059% CN¥ 3.5m
Ming Tu	CFO & Executive VP	2.4yrs	no data	no data
Tang Shaogui	VP and Head of Global Communications	no data	no data	no data
Sherry Gu	Chief Technology Officer and Executive VP of Global Biologics Development Department	less than a year	no data	no data
Jijie Gu	Executive VP & Chief Scientific Officer	no data	no data	no data
Eileen Wang	IR Senior Director	no data	no data	no data
Cong Ding	VP & Head of Legal Department	no data	no data	no data
He Wang	Chief Compliance Officer	1.6yrs	no data	no data
Li Xiong	VP & Head of Global Human Resources	no data	no data	no data
Angus Scott Turner	Senior VP and Head of Global BD & Alliance Management	no data	no data	no data

2.4yrs

Average Tenure

55yo

Average Age

Experienced Management: 2269's management team is considered experienced (2.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ge Li	Founder & Chairman	10.2yrs	no data	no data
Zhisheng Chen	CEO & Executive Director	10.2yrs	CN¥78.67m	0.32% CN¥ 184.2m
Weichang Zhou	Honorary President of Global Biologics Development	7.9yrs	CN¥24.98m	0.0059% CN¥ 3.5m
Jackson Tai	Independent Non-Executive Director	less than a year	no data	0.00062% CN¥ 360.3k
James Larrick	Member of Scientific Advisory Board	6.3yrs	no data	no data
David D. Ho	Member of Scientific Advisory Board	6.3yrs	no data	no data
Wei-Shou Hu	Member of Scientific Advisory Board	6.3yrs	no data	no data
Ram Sasisekharan	Member of Scientific Advisory Board	6.3yrs	no data	no data
William Robert Keller	Independent Non-Executive Director	6.9yrs	CN¥570.00k	0.00053% CN¥ 308.0k
Yanling Cao	Non-Executive Director	7.9yrs	no data	no data
Yibing Wu	Non-Executive Director	7.9yrs	no data	no data
Kenneth Walton Hitchner	Independent Non-Executive Director	3.8yrs	CN¥621.00k	0.0049% CN¥ 2.8m

6.6yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 2269's board of directors are considered experienced (6.6 years average tenure).

WuXi Biologics (Cayman) Management

Management criteria checks 2/4

Key information

Recent management updates

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

CEO & Executive Director recently sold HK$6.0m worth of stock

Recent updates

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Less than half of directors are independent

Consensus EPS estimates fall by 18%

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

Investor sentiment deteriorates as stock falls 16%

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 18%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 21%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Investor sentiment improves as stock rises 16%

Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New minor risk - Share price stability

Consensus revenue estimates fall by 14%

Investor sentiment deteriorates as stock falls 28%

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Now 20% undervalued

Board Member recently sold HK$25m worth of stock

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Investor sentiment improves as stock rises 16%

What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

CEO & Executive Director recently sold HK$4.6m worth of stock

Investor sentiment deteriorates as stock falls 20%

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

CEO & Executive Director recently sold HK$13m worth of stock

Now 21% undervalued after recent price drop

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Now 22% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Now 20% undervalued after recent price drop

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS misses analyst expectations

At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Investor sentiment improved over the past week

Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching

Less than half of directors are independent

With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case

Investor sentiment improved over the past week

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?

Investor sentiment deteriorated over the past week

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.